Skip to content
Subscriber Only

Pfizer Pipeline Bet to Show If Drugmaker Has Blockbuster

Pfizer Inc.’s Chief Executive Officer Ian Read will find out in the next six months whether his plan to shed units and focus on new drugs will pay off, with three top products awaiting approval or key data.

U.S. Food and Drug Administration regulators will rule on Pfizer’s blood thinner and arthritis pill by June and August, respectively. The New York-based company plans to report data from the last of three phases of clinical tests on bapineuzumab, its experimental Alzheimer’s treatment, in the third quarter.